CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8) Applicant(s): ABNEY, et al.			Docket No. PR60153US1
Serial No. 10/619,766	Filing Date 07/15/2003	Examiner	Group Art Unit 1614

Invention:

PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING LITHIUM CARBONATE, PROCESSES OF MAKING THE SAME, AND METHODS OF ADMINSTERING THE SAME

I hereby certify that this **IDS**
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

on 10/6/03
(Date)

Ban Younan
(Typed or Printed Name of Person Mailing Correspondence)

Ban Younan
(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

PR60153US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:	**ABNEY, et. al.**		
Serial No.:	**10/619,766**	Group Art Unit:	**1614**
Filed:	**07/15/2003**	Examiner:	

For: **PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING LITHIUM CARBONATE, PROCESSES OF MAKING THE SAME, AND METHODS OF ADMINSTERING THE SAME**

Director of the United States Patent and Trademark Office
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[X] Copies of the references are enclosed: **1-42**
[] Copies of the references were submitted in parent application Serial No. (37 CFR 1.98(d))
[] A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[] **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

B. [] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,

whichever occurs first.

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) ($240.00).

C. [] The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the

issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

[] The petition fee set forth in § 1.17(i)(1) ($130.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.
[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Attorney of Record: **Robert J. Smith**
Registration No.: **40,820**
Telephone: (919) 483-**9616**

Customer No.: 23347

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: PR60153US	SERIAL NO: 10/619,766
	APPLICANT:	
	FILING DATE: 07/15/2003	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	4264573	04/28/1981	POWELL et. al.			
	2	4695591	09/22/1987	HANNA et. al.			
	3	5300300	04/02/1994	EGIDIO et. al.			
	4	5302398	04/12/1994	EGIDIO et. al.			
	5	5445829	08/29/1995	PARADISSIS et. al.			
	6	5558879	09/24/1996	CHEN et. al.			
	7	5654005	08/05/1997	CHEN et. al.			
	8	6210710	04/03/2001	SKINNER			
	9	6358525	03/19/2002	GUO et. al.			
	10	6426087	07/30/2002	SASLAWSKI et. al.			
	11	6500459	12/31/2002	CHHABRA et. al.			

Continued on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes | No
	12	2016922	09/26/1979	GB			X
	13	0093538	11/09/1983	EP			X
	14	0284849	10/05/1988	EP			X
	15	0471100	02/19/1992	EP			X
	16	9427557	12/08/1994	PCT			X
	17	9640080	12/19/1996	PCT			X
	18	9917751	04/15/1999	PCT			X

Continued on page 2

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	25	United States Patent Application Publication; 2002/0172727 A1; 11/21/2002; 1-6; VALDUCCI
	26	Farina et. al.; *Statistical Comparison of the Dissolution Curves of Controlled Release Solid Oral Dosage Forms*; Drig Development and Industrial Pharmacy; 1987; 13; 1107-1118
	27	Jedras et. al.; *In Vitro and In Vitro Release of Lithium from Lithium Sulphate-Gastrointestinal Diffusion System*; Journal of Controlled Release; 1989; 9, No. 1; 13-19
	28	De Haan et. al.; *Oral Controlled Dosage Forms. A Review.*; Pharmaceutisch Weekblad Scientific Edition; 1984; 6 (2); 57-67
	29	Ansari et. al.; *Studies on Oral Controlled Release Pellets of Lithium Carbonate*; Indian Journal of Pharmaceutical Sciences; 2000; 62 (6); 512
	30	Jedras et. al.; *Kinetics of Lithium Release In Vitro from an Oral Therapeutic System*; Farmacja Polska; 1984; 40 (8); 471-474
	31	Janicki et. al.; *Method of Preparing and Pharmaceutical Availability of Pellets of Lithium Carbonate with Controlled Release;* Farmacja Polska; 2000; 56; 763-766
	32	Davis; *The Design and Evaluation of Controlled Release Dosage Forms for Oral Delivery*; STP Pharma; 1987; 3 (5); 412-417

Continued on page 2

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: PR60153US	SERIAL NO: 10/619,766
	APPLICANT:	
	FILING DATE: 07/15/2003	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continued on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes | No
	19	0151035	07/19/2001	PCT			X
	20	0151040	07/19/2001	PCT			X
	21	0151041	07/19/2001	PCT			X
	22	0166081	09/13/2001	PCT			X(Abstract Only)
	23	0180824	11/01/2001	PCT			X
	24	0211740	02/14/2002	PCT			X

Continued on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	33	Solodkaya et. al.; *Preparation and Properties of Micalith Tablets*; Farmatsiya; 1983; 32; 29-32
	34	Janicki et. al.; *A Study In Vitro of Lithium Release from a Multi-Compartment Gastrointestinal Diffusion System*; Farmacja Polska; 1989; No. 6; 382-387
	35	Janicki el al.; *Preparation of a Lithium Gastrointestinal Diffusion System*; Farmacja Polska; 1988; No. 6/1; 331-333
	36	Arancibia et. al.; *Formulation and "In Vitro" Evaluation of a Controlled Release Lithium Carbonate Tablet*; Anales de la Real Academia de Farmacia; 1990; 56; 333-346
	37	Jedras et. al.; *Lithium Sulphate Gastrointestinal Diffusion System: How to Avoid A Lag-Time Effect?*; Pharmazie; 1991; 46; H. 7; 536-537
	38	Graffner et. al.; *Testing Delivery Times*; Manufacturing Chemist; September 1989; 50-53
	39	Jedras et. al.; *Lithium Acetate Gastrointestinal Diffusion System Part 2. Lithium Acetate Multi-Unit Gastrointestinal Diffusion System: Preparation and Release Rate Studies*; Pharmazie; 1990; 45; H.2; 116-118
	40	Janicki et. al.; *Lithium Acetate Gastrointestinal Diffusion System Part 1. Lithium Acetate Single-Unit Gastrointestinal Diffusion System: Preparation and Release Rate Studies*; Pharmazie; 1990; 45; H. 1; 45-47
	41	Ventouras; *In Vitro Release of Lithium Sulfate from Hydrophilic Matrices;* Pharmaceutica Acta Helvetiae; 1976; 51; 212-218
	42	Graf et. al.; *Pharmaceutical Presentation Forms: Yesterday-Today-Tomorrow*; Pharm. Unserer Zeit; 1991; 20; No. 2; 64-74

Continued on page

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.